Please note that following on from information provided to NICE by the company in February 2018, the appraisal of Biotin for treating primary and secondary progressive multiple sclerosis [ID919] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 919
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Medday Pharmaceuticals
- Others
- Department of Health
- NHS East Riding of Yorkshire CCG
- NHS England
- NHS Haringey CCG
- Welsh Government
- Patient carer groups
- Brain and Spine Foundation
- The Brain Charity
- Disability Rights UK
- Leonard Cheshire Disability
- MS-UK
- Multiple Sclerosis National Therapy Centres
- Multiple Sclerosis Society
- Multiple Sclerosis Trust
- Muslim Council of Britain
- Neurological Alliance
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder
- Professional groups
- Association of British Neurologists
- British Geriatrics Society
- British Neuropathological Society
- Institute of Neurology
- Primary Care Neurology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Therapists in MS
- UK Clinical Pharmacy Association
- UK Multiple Sclerosis Specialist Nurse Association
- Associated public health groups
- Public Health England
- Public Health Wales
- Comparator companies
- Roche (ocrelizumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- Multiple Sclerosis Society Wales
- National Association of Primary Care
- National Pharmacy Association
- Neurological Alliance of Scotland
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium
- Wales Neurological Alliance
- Welsh Health Specialised Services Committee
- Relevant research groups
- Brain Research Trust
- British Neurological Research Trust
- Cochrane Multiple Sclerosis Group
- MRC Clinical Trials Unit
- National Hospital for Neurology and Neurosurgery
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in February 2018, the appraisal of Biotin for treating primary and secondary progressive multiple sclerosis [ID919] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 February 2018 | Suspended. The company have notified the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that it wishes to withdraw its application for a marketing authorisation for biotin (Qizenday), for the treatment of progressive multiple sclerosis. This appraisal will therefore now be suspended. |
| 01 November 2017 | Invitation to participate |
| 01 September 2016 | Draft scope documents |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual